Quantum-Si Incorporated
QSI Healthcare Medical Devices
Quantum-Si Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $2.4 million, down 20.3% from fiscal 2024. In the quarter to June 2026, revenue fell 41.8%, EPS grew 31.3% and free cash flow grew 9.75%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow QSI
Quantum-Si Incorporated (QSI) EV/Sales
As of 16 October 2026, Quantum-Si Incorporated (QSI) trades at a EV/Sales of 82.4×. Over the past ten years it has ranged from −90.5× (June 2024) to 141× (October 2026); the current reading is higher than 99% of that period. That is above the Medical Devices industry median of 2.2× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 22.4× | (61.26%) |
| FY2024 | 57.9× | 115.22% |
| FY2023 | 26.9× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 51.2× | 140.79% |
| Mar 2026 | 21.2× | (5.27%) |
| Dec 2025 | 22.4× | 3.40% |
| Sep 2025 | 21.7× | (49.21%) |
| 10 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| LAB Standard BioTools Inc. compare | −2.7× |
| RCEL Avita Medical Inc. compare | 1.3× |
| TMCI Treace Medical Concepts, Inc. compare | 1.3× |
| INFU InfuSystems Holdings, Inc. compare | 2.0× |
| TLSI TriSalus Life Sciences, Inc. compare | 4.4× |
| CLPT ClearPoint Neuro, Inc. compare | 7.0× |
| CV CapsoVision, Inc. compare | 22.8× |
| CATX Perspective Therapeutics, Inc. compare | 64.7× |
| QSI Quantum-Si Incorporated | 82.4× |
| Medical Devices industry median | 2.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)